---
title: "ELVN.US (ELVN.US) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/ELVN.US/news.md"
symbol: "ELVN.US"
name: "ELVN.US"
parent: "https://longbridge.com/zh-HK/quote/ELVN.US.md"
datetime: "2026-03-15T19:21:44.375Z"
locales:
  - [en](https://longbridge.com/en/quote/ELVN.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ELVN.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ELVN.US/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/ELVN.US/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/ELVN.US/news.md)


# ELVN.US (ELVN.US) — 相關新聞

### [Enliven Therapeutics Q4 earnings missed by -6.67%, EPS $-0.48 vs. estimate of $-0.45. Revenue flat compared to last year.](https://longbridge.com/zh-HK/news/277685205.md)
*2026-03-03T21:50:54.000Z*
> Enliven Therapeutics (NASDAQ: ELVN) unveiled its Q4 financial results on March 3, 2026, at 04:05 PM. The key highlights 

### [Enliven Therapeutics GAAP EPS of -$0.48 misses by $0.09](https://longbridge.com/zh-HK/news/277680289.md)
*2026-03-03T21:32:29.000Z*
> Enliven Therapeutics GAAP EPS of -$0.48 misses by $0.09

### [Enliven Therapeutics Q4 net loss widens on higher expenses](https://longbridge.com/zh-HK/news/277680010.md)
*2026-03-03T21:29:23.000Z*
### [Enliven Therapeutics | 8-K: FY2025 Q4 Revenue: USD 0](https://longbridge.com/zh-HK/news/277678746.md)
*2026-03-03T21:15:57.000Z*
### [Enliven Therapeutics (NASDAQ:ELVN) Director Sells $32,201.40 in Stock](https://longbridge.com/zh-HK/news/276398227.md)
*2026-02-20T01:07:15.000Z*
> Enliven Therapeutics Director Richard Heyman sold 1,230 shares of the company's stock for $32,201.40 at an average price

### [Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) Insider Sells 5,000 Shares of Stock](https://longbridge.com/zh-HK/news/275591052.md)
*2026-02-11T10:45:26.000Z*
> Enliven Therapeutics insider Joseph Lyssikatos sold 5,000 shares at $29.04 each, totaling $145,200, reducing his ownersh

### [Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos Reports Disposal of Common Shares](https://longbridge.com/zh-HK/news/275523266.md)
*2026-02-10T23:12:42.000Z*
### [Enliven Therapeutics (NASDAQ:ELVN) Director Sells 1,230 Shares](https://longbridge.com/zh-HK/news/273435509.md)
*2026-01-22T23:09:09.000Z*
> Enliven Therapeutics Director Richard Heyman sold 1,230 shares at $26.75 each, totaling $32,902.50, reducing his ownersh